Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new way to kill cancer: SLU research shows viruses can destroy lung, colon tumors

17.05.2004


Research published this month: Healthy tissue left intact in pre-clinical testing



A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.

The research could lead to a new class of cancer therapies that selectively kill cancer cells.


"These engineered viruses kill cancer cells through a mechanism that is completely different from chemotherapy or radiation," said Dr. William Wold, chair of the department of molecular microbiology and immunology at Saint Louis University School of Medicine. "These viruses have the potential to treat many cancers that are resistant to currently available therapeutics. It also may be possible to use these viruses in combination with other therapies to create novel treatment regimens."

Dr. Wold and his colleagues Karoly Toth, Konstantin Doronin, Ann E. Tollefson, Mohan Kuppuswamy, Baoling Ying, Jacqueline Spencer, and Maria Thomas have been researching for many years ways to convert the relatively benign "adenovirus" that causes symptoms similar to the common cold in children into an anti-cancer drug that attacks and destroys cancerous cells.

Wold’s group has developed several new "adenovirus cancer gene therapy vectors," changing these genes so the virus will attack cancer cells.

"Some of our vectors are designed to destroy many different types of cancers, others are designed to be specific to colon or lung cancer. In preclinical testing these vectors were highly effective against cancerous tumors and did not harm normal tissues."

The new research reported today in Cancer Research involves INGN 007 (VRX-007) and INGN 009 (VRX-009), two novel "oncolytic adenoviruses" that have been engineered to kill cancer cells via viral replication. These viruses can be engineered so that they are active in specific types of cancer cells. The data published today indicate that both efficiently killed cancer cells in culture. Specifically:

INGN 009, which has been designed to kill cells that carry a mutation common in many colon cancers, efficiently killed cultured colon cancer cells, but not lung cancer cells.

INGN 007 effectively killed both types of cancer cells. In an animal model of colon cancer, injection of either INGN 007 or INGN 009 into tumors suppressed tumor growth more efficiently than a negative control (five-fold and ten-fold suppression, respectively).

INGN 007 also completely suppressed tumor growth in a lung cancer model of disease.
Louis Zumstein, Ph.D., director of research at Introgen Therapeutics Inc., which has licensed rights to these oncolytic viruses and other related technologies, said: "These preclinical data are very promising, and support our belief that oncolytic adenoviruses have enormous potential as a new class of cancer therapies that may provide potent and selective killing of cancer cells. These data also illustrate the flexibility of engineered oncolytic adenoviruses to target selected tumor types with great specificity."

A U.S. patent (No. 6,627,190) for this technology was awarded last year to Dr. Wold and his team of researchers. Introgen and VirRx, a biotechnology company founded by Wold and with a primary interest in cancer gene therapy, are collaborating on new therapies for cancer and other diseases. Introgen is a leading developer of biopharmaceutical products that use non-integrating genes to produce a therapeutic protein to treat cancer and other diseases. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a commercial- scale, CGMP manufacturing facility.


Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first M.D. degree west of the Mississippi River. Saint Louis University School of Medicine is a pioneer in geriatric medicine, organ transplantation, chronic disease prevention, cardiovascular disease, neurosciences and vaccine research, among others. The School of Medicine trains physicians and biomedical scientists, conducts medical research, and provides health services on a local, national and international level.

Joe Muehlenkamp | EurekAlert!
Further information:
http://www.slu.edu/

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>